Table 4.
Safety table
| Safety population (n=20) | ||
| Any grade | Grade 3–4 | |
| N (%) | N (%) | |
| Any AE | 20 (100) | 8 (40) |
| TRAE | 16 (80) | 5 (25) |
| Neutrophil count decreased | 4 (20) | 2 (10) |
| Platelet count decreased | 4 (20) | 1 (5) |
| Alanine transaminase increased | 4 (20) | 0 |
| Aspartate transaminase increased | 4 (20) | 0 |
| Anorexia | 2 (10) | 0 |
| Fatigue | 2 (10) | 0 |
| Cold symptoms | 2 (10) | 0 |
| Colitis | 1 (5) | 1 (5) |
| Infusion-related reaction | 1 (5) | 1 (5) |
| Septic shock | 1 (5) | 1 (5) |
| Abdominal pain | 1 (5) | 0 |
| Dry eyes | 1 (5) | 0 |
| Dry mouth | 1 (5) | 0 |
| Eczema | 1 (5) | 0 |
| Headache | 1 (5) | 0 |
| Hoarseness | 1 (5) | 0 |
| Nausea | 1 (5) | 0 |
| Pruritus | 1 (5) | 0 |
| Rhinitis | 1 (5) | 0 |
| Urinary tract infection | 1 (5) | 0 |
| Vomiting | 1 (5) | 0 |
AE, adverse event; TRAE, treatment-related AE.